We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Gossypol Reverses Chemo Resistance

By Biotechdaily staff writers
Posted on 08 Aug 2005
Researchers studying the relationship between fatty deposits in the liver (steatosis) and insulin resistance have found that the enzyme mitochondrial acyl-CoA:glycerol-sn-3-phosphate acyltransferase 1 (mtGPAT1) plays a key role in the development of insulin resistance and should be considered a target for treatment of diabetes.

Investigators at Yale University (New Haven, CT, USA) genetically engineered a line of mice to lack the gene for production of mtGPAT1. More...
These animals and a control group with normal levels of mtGPAT1 were placed on high-fat diets.

After three weeks, mice lacking mtGPAT1 had markedly lower than normal concentrations of the liver lipid metabolites hepatic triacylglycerol and diacylglycerol. Compared to normal mice, the animals also were protected from hepatic insulin resistance. Furthermore, results published in the July 2005 issue of Cell Metabolism revealed that the mice lacking mtGPAT1 exhibited increased hepatic insulin sensitivity despite an almost 2-fold elevation in levels of hepatic acyl-CoA, a substance previously linked to insulin resistance. This finding suggests that long chain acyl-CoA's do not mediate fat-induced hepatic insulin resistance in this model, and that mtGPAT1 might serve as a novel target for treatment of hepatic steatosis and hepatic insulin resistance.

Senior author Dr. Gerald Shulman, professor of medicine at Yale University, said, "Through noninvasive measurements of hepatic triglyceride content in humans, we have learned that elevated liver fat is fairly ubiquitous in patients with poorly controlled type 2 diabetes. It has been an under-appreciated aspect of the disease.”

Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
Gold Member
Automatic Hematology Analyzer
CF9600
New
POC Immunoassay Analyzer
Procise DX
New
All-in-One Molecular System
AIO M160
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.